2021
mRNA vaccine enters trials
- About
- Our Business
- Research
-
Manufacturing
- Financials
- Blog
- Careers
- Newsroom
- Contact
mRNA vaccine enters trials
Sanand Injectables facility commenced USFDA approval of Sanand and F-II (API).
TENECTASE approved as emergency care for stroke
US manufacturing facility expansion
Acquired Bharadwaj Pharma GMBH in Germany
Acquired Marcan Pharmaceuticals Inc., Canada
Acquired Tillomed Laboratories, United Kingdom. Bain capital acquired Blackstone’s stake in Emcure
Worldwide rights of BICNU acquired.
Commenced EU operations with
formation of Emcure UK
Cytotoxic facility commenced in Hinjewadi
Solid Dosage facility commenced in Jammu
USFDA approvals received for injectable facility at Hinjewadi.
First in-house biosimilar TNK-Tpa launched
Blackstone’s first investment in India at Emcure API facility at
Kurkumbh commenced.
Injectable & Emcure Biotech Ltd. (now Gennova
biopharmaceuticals limited) facility operational
Solid Oral Facility at Hinjawadi commenced & first USFDA approval granted
Emcure Pharmaceutical USA (now Heritage Pharmaceutical Labs) incorporated & in-house API R&D commenced
Zuventus Healthcare Limited incorporated & First Chiral product launched
Gennova Biopharmaceuticals Limited incorporated
Launched Indian Formulation Business
First manufacturing facility operational in Bhosari
Emcure Pharmaceuticals Private Limited incorporated
